News

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The allogeneic mesenchymal stem cell therapy trial will enroll patients ineligible for treatment with the autologous CardiAMP.

The first 2 participants dosed are free of vaso-occlusive events as of 5 and 1.5 months of follow-up after treatment with EDIT-301.

Ivan Horak, MD, discussed Tessa’s cell therapy platforms and the ACTION clinical trial.

Updated data were presented at the AES annual meeting in Nashville.

Patients with non-Hodgkin lymphoma in Nkarta's phase 1 study had a 75% complete response rate.

The associate professor from the Medical College of Wisconsin discussed how to address unmet needs with CAR T-cell therapies.

Initial safety data from the PRODYGY study are expected in 2023.

Beam Therapeutics provided data on genomic rearrangement, off-target edits and from a cytokine independent growth assay to the FDA in November 2022.

Updated data from 3 of the company’s programs were presented at an R&D showcase.

OPGx-001 is the first of Opus Genetics’ gene therapy candidates for treating LCA to enter clinical trials.

Sensorion indicated it is still on track to submit a clinical trial application in the first half of next year.

The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Lysogene’s MPS IIIA gene therapy program recently failed its primary endpoint in the phase 2/3 AAVANCE trial.

The FDA has decided not to hold an advisory committee meeting for Roctavian after all.

CB-010 most recently demonstrated a 100% complete response rate in data presented at the EHA 2022 congress.

BEAM-101 is edited with a next-generation CRIPSR product to mimic single nucleotide polymorphisms that enable persistence of fetal hemoglobin.

In preclinical research, TN-401 was shown to significantly increase the lifespan of PKP2-knock-out mice.

SRP-9001's PDUFA date is set for May 23, 2023.

Review top news and interview highlights from the week ending November 25, 2022.

The first participant has been followed-up for 3 months so far after treatment while the second is only 1 week post-treatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A marketing authorization application for etranacogene dezaparvovec is currently under review by the EMA.

The IND clearance comes after Legend terminated another clinical trial in T-cell lymphoma in July 2022.

Thomas Willemsen, president and chief executive officer, Tessa Therapeutics, discussed the company’s technologies and 2023 milestones.

The phase 1 clinical trial plans to initiate enrollment in early 2023.

SRD-001 is designed to increase expression and functional activity of SERCA2a, down-regulation of which is associated with all forms of heart failure.